Liu Tie

Liu Tie has extensive work experience in the pharmaceutical and biotechnology industry. They most recently worked at Transcenta as the Executive Director of Analytical Science, starting in March 2021. Prior to that, they held the position of Head of Analytical Operation at Bristol Myers Squibb from January 2020 to March 2021.

In 2019, Liu Tie served as the Head of CMC (Chemistry, Manufacturing, and Controls) in Bioanalytical at HARBOUR BIOMED. In this role, they were responsible for project planning, process development, and regulatory planning for late-stage projects.

From 2018 to 2019, Liu Tie was a Senior Group Leader in Analytical Development at Pfizer, where they led analytical strategies, authored analytical sections for submissions, and coordinated method development activities globally.

Prior to Pfizer, Liu Tie worked at MedImmune, AstraZeneca from 2008 to 2018 as the CMC Analytical Lead. Their responsibilities included preparing specifications, implementing quality by design principles, and responding to regulatory inquiries.

Liu Tie's career began at Human Genome Sciences in 2002, where they served as a Senior Associate Scientist. They conducted therapeutic antibody characterization and contributed to analytical method development for regulatory filings.

Their earliest experience was at BioReliance, where they started as a Scientist in 1997. They conducted GLP/GMP analytical testing, method validation, and provided technical support for protein analysis.

Overall, Liu Tie has a diverse range of experience in analytical science, CMC, and regulatory affairs in the pharmaceutical industry.

Liu Tie's education history includes a Bachelor of Science degree in Analytical Chemistry from Fudan University. The dates of enrollment for this degree are not specified. Liu Tie also pursued a Master of Science degree in Bioanalytical Chemistry from the East Tennessee State University James H. Quillen College of Medicine. The specific dates of enrollment for this degree are also not provided.